ConCallIQ
Go Pro
ORIENTALAROMATICS Diversified 10 Feb 2026

Oriental Aromatics Limited — Q3 FY26

Oriental Aromatics reported Q3 FY26 revenue of ₹252 cr (+13% YoY), but EBITDA margin contracted sharply to 5.26% (down ~559 bps YoY) and PAT swung to a loss of ₹1.92 cr.

bearish medium
Compare with...
Revenue ₹252 Cr +13%
EBITDA ₹13 Cr -43.48%
PAT ₹-2 Cr -126.89%
EBITDA Margin 5.26% -559bps
Duration 44 min
Read Time 1 min read

✓ Verified against BSE filing

2-Minute Summary

✦ AI-Generated from Full Transcript

Oriental Aromatics reported Q3 FY26 revenue of ₹252 cr (+13% YoY), but EBITDA margin contracted sharply to 5.26% (down ~559 bps YoY) and PAT swung to a loss of ₹1.92 cr. Volume growth remained healthy (sales +10% YoY), driven by market share gains in a soft pricing environment. However, margin compression persisted due to pricing pressure in aroma ingredients, unfavorable seasonal mix (post-festive camper slowdown), and the drag from Mahad's greenfield ramp-up (still at 30-35% utilization). Management guided for 8-10% full-year revenue growth and expects Mahad to reach breakeven in 2-3 quarters as commercial shipments ramp up. The recent US-India trade deal (tariff reduction to 18%) is seen as a positive catalyst for North American demand. Key risk: if pricing recovery is delayed or Mahad stabilization takes longer than expected, margins could remain under pressure.

Risks3 trackedTranscriptfull text
Research workspace

Focused Modules

!Risks 3 risks

Risk Intelligence

Pricing recovery may be delayed

View Risks →
Transcript Full text

Call Transcript

Full transcript text is available on this route.

Read Transcript →

Quarter Snapshot

Sales Volume Growth (YoY) 10%
+10% YoY

Total sales volumes increased 10% year-on-year in Q3, driven by market share gains.

Production Growth (YoY) 3%
+3% YoY

Total production grew 3% YoY in Q3, reflecting steady operations.

Mahad Capacity Utilization 30-35%
N/A

Mahad plant is running at 30-35% capacity, still in early ramp-up phase.

Net Debt to Equity 0.65x
N/A

Balance sheet remains healthy with net debt-to-equity at 0.65x as of Dec 2025.

Fast read

Guidance and risk preview

Top guidance Full-year revenue growth of 8-10%

Management expects FY26 revenue growth of 8-10% YoY, driven by volume gains and market share expansion.

Top risk Pricing recovery may be delayed

Aroma ingredient pricing remains under pressure due to a buyer's market and Chinese competition; recovery timing is uncertain.

View Risks →